Esmolol
Trade names |
Brevibloc |
---|---|
Clinical data | |
Drug class |
Beta blocker |
Routes of administration |
Intravenous |
Dosage |
Attenuating cardiovascular response to laryngoscopy: Adult: 0.2-0.5 mg/kg IV bolus Perioperative tachycardia and hypertension: Adult: 0.5-1 mg/kg IV bolus. Can start an infusion at 50 mcg/kg/minute and titrate up to a maximum rate of 300 mcg/kg/minute. |
Dosage | |
Pharmacodynamics | |
Mechanism of action |
Beta-1 antagonism |
Adverse effects |
Bradycardia, Hypotension |
Pharmacokinetics | |
Physical and chemical data | |
Article quality | |
Editor rating | |
User likes | 0 |
Esmolol is an ultrashort-acting selective β1-antagonist. It primarily decreases heart rate with less of an effect on blood pressure. [1]
Uses
Treat/prevent perioperative tachycardia and hypertension .
Opioid sparing anesthesia.[1]
Contraindications
Absolute contraindications
Precautions
While it is cardioselective at lower doses, use higher doses cautiously in patients with bronchospastic disease. [2]
Extreme caution should be used in patients with bradycardia, hypotension, greater than first degree heart block, cardiogenic shock or heart failure with reduced ejection fraction.[1] Avoid in patients who recently received a calcium channel blocker. [2]
Pharmacology
Pharmacodynamics
Mechanism of action
At normal doses it is a selective β1-antagonist, at higher doses it also inhibits β2 receptors in both bronchial and vascular smooth muscle. [1]
Adverse effects
Pharmacokinetics
Chemistry and formulation
History
References
- ↑ 1.0 1.1 1.2 1.3 Morgan & Mikhail's clinical anesthesiology. John F., IV Butterworth, David C. Mackey, John D. Wasnick (Seventh edition ed.). New York. 2022. ISBN 9781260473797. OCLC 1309921315.
|edition=
has extra text (help)CS1 maint: others (link) - ↑ 2.0 2.1 "UpToDate - Esmolol: Drug information". www.uptodate.com. Retrieved 2022-12-21.